Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL (original) (raw)

Nature Genetics volume 39, pages 513–516 (2007)Cite this article

Abstract

Resequencing genes provides the opportunity to assess the full spectrum of variants that influence complex traits. Here we report the first application of resequencing to a large population (n = 3,551) to examine the role of the adipokine ANGPTL4 in lipid metabolism. Nonsynonymous variants in ANGPTL4 were more prevalent in individuals with triglyceride levels in the lowest quartile than in individuals with levels in the highest quartile (P = 0.016). One variant (E40K), present in ∼3% of European Americans, was associated with significantly lower plasma levels of triglyceride and higher levels of high-density lipoprotein cholesterol in European Americans from the Atherosclerosis Risk in Communities Study and in Danes from the Copenhagen City Heart Study. The ratio of nonsynonymous to synonymous variants was higher in European Americans than in African Americans (4:1 versus 1.3:1), suggesting population-specific relaxation of purifying selection. Thus, resequencing of ANGPTL4 in a multiethnic population allowed analysis of the phenotypic effects of both rare and common variants while taking advantage of genetic variation arising from ethnic differences in population history.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Rondinone, C.M. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29, 81–90 (2006).
    Article CAS Google Scholar
  2. Li, C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr. Opin. Lipidol. 17, 152–156 (2006).
    Article CAS Google Scholar
  3. Koster, A. et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146, 4943–4950 (2005).
    Article CAS Google Scholar
  4. Yoshida, K., Shimizugawa, T., Ono, M. & Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43, 1770–1772 (2002).
    Article CAS Google Scholar
  5. Xu, A. et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. USA 102, 6086–6091 (2005).
    Article CAS Google Scholar
  6. Mandard, S. et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281, 934–944 (2006).
    Article CAS Google Scholar
  7. Merkel, M., Eckel, R.H. & Goldberg, I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43, 1997–2006 (2002).
    Article CAS Google Scholar
  8. Yu, X. et al. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl. Acad. Sci. USA 102, 1767–1772 (2005).
    Article CAS Google Scholar
  9. Victor, R.G. et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am. J. Cardiol. 93, 1473–1480 (2004).
    Article Google Scholar
  10. Browning, J.D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395 (2004).
    Article Google Scholar
  11. Grundy, S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81, 18B–25B (1998).
    Article CAS Google Scholar
  12. The ARIC Study Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am. J. Epidemiol. 129, 687–702 (1989).
  13. Schnohr, P., Jensen, G., Scharling, H. & Appleyard, M. The Copenhagen City Heart Study. Osterbroundersogelsen. Tables with data from the third examination 1991–94. Eur. Heart J. 3 (Suppl.), H1–H83 (2001).
    Google Scholar
  14. Tajima, F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123, 585–595 (1989).
    CAS PubMed PubMed Central Google Scholar
  15. Fu, Y.X. & Li, W.H. Statistical tests of neutrality of mutations. Genetics 133, 693–709 (1993).
    CAS PubMed PubMed Central Google Scholar
  16. Collins, F.S. The case for a US prospective cohort study of genes and environment. Nature 429, 475–477 (2004).
    Article CAS Google Scholar
  17. Gibbs, R. Deeper into the genome. Nature 437, 1233–1234 (2005).
    Article CAS Google Scholar
  18. Kotowski, I.K. et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410–422 (2006).
    Article CAS Google Scholar
  19. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161–165 (2005).
    Article CAS Google Scholar
  20. Cohen, J.C. et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA 103, 1810–1815 (2006).
    Article CAS Google Scholar
  21. Tartaglia, M. et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet. 39, 75–79 (2007).
    Article CAS Google Scholar

Download references

Acknowledgements

The authors thank the Joint Genome Institute's production sequencing group, T. Hyatt, K. Moller Hansen, M. Refstrup, W.S. Schackwitz, J. Martin and A. Ustaszewska for excellent technical assistance and J. Schageman, C. Lee and K. Lawson for statistical analyses. We are indebted to the staff and participants of the Dallas Heart Study, the ARIC study and the CCHS for their important contributions. We thank J. Goldstein and M. Brown for discussions. This work was supported by grants from the Donald W. Reynolds Foundation, the US National Institutes of Health, the Danish Medical Research Council, The Danish Heart Foundation and the Research Fund at Rigshospitalet (Copenhagen University Hospital). Research conducted at the E.O. Lawrence Berkeley National Laboratory and the Joint Genome Institute was performed under the Berkeley Program for Genomic Applications, funded by the US National Heart, Lung, and Blood Institute (HL066681) and Department of Energy Contract DE-AC02-05CH11231 (University of California).

Author information

Author notes

  1. Stefano Romeo and Len A Pennacchio: These authors contributed equally to this work.

Authors and Affiliations

  1. Donald W. Reynolds Cardiovascular Clinical Research Center, the Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA.,
    Stefano Romeo, Helen H Hobbs & Jonathan C Cohen
  2. Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, 94720, California, USA
    Len A Pennacchio
  3. US Department of Energy Joint Genome Institute, Walnut Creek, 94598, California, USA
    Len A Pennacchio
  4. Human Genetics Center and Institute for Molecular Medicine, University of Texas Health Science Center, Houston, 77030, Texas, USA
    Yunxin Fu & Eric Boerwinkle
  5. Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK-2100, Denmark
    Anne Tybjaerg-Hansen
  6. Center for Human Nutrition and the University of Texas Southwestern Medical Center, Dallas, 75390, Texas, USA
    Jonathan C Cohen
  7. Howard Hughes Medical Center at the University of Texas Southwestern Medical Center, Dallas, 75390, Texas, USA
    Helen H Hobbs

Authors

  1. Stefano Romeo
    You can also search for this author inPubMed Google Scholar
  2. Len A Pennacchio
    You can also search for this author inPubMed Google Scholar
  3. Yunxin Fu
    You can also search for this author inPubMed Google Scholar
  4. Eric Boerwinkle
    You can also search for this author inPubMed Google Scholar
  5. Anne Tybjaerg-Hansen
    You can also search for this author inPubMed Google Scholar
  6. Helen H Hobbs
    You can also search for this author inPubMed Google Scholar
  7. Jonathan C Cohen
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toHelen H Hobbs or Jonathan C Cohen.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Location and frequency of sequence variations identified in ANGPTL4. (PDF 159 kb)

Supplementary Table 1

Oligonucleotide primers used for amplification and sequencing of ANGPTL4. (PDF 13 kb)

Supplementary Table 2

Distribution of nonsynonymous and synonymous sequence variants in the Dallas Heart Study. (PDF 19 kb)

Supplementary Table 3

Nonsynonymous ANGPTL4 alleles in individuals with high and low BMI, HDL-C and plasma insulin levels in the Dallas Heart Study. (PDF 22 kb)

Supplementary Table 4

Association between sequence variants in ANGPTL4 and plasma triglyceride levels in the Dallas Heart Study. (PDF 92 kb)

Supplementary Table 5

Association between _ANGPTL4_[E40K] genotype and plasma triglyceride levels in African Americans and Hispanics. (PDF 86 kb)

Supplementary Table 6

Tests for neutrality of mutations in the Dallas Heart Study. (PDF 33 kb)

Supplementary Note (PDF 17 kb)

Rights and permissions

About this article

Cite this article

Romeo, S., Pennacchio, L., Fu, Y. et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL.Nat Genet 39, 513–516 (2007). https://doi.org/10.1038/ng1984

Download citation

This article is cited by

Associated content